Stoke has obtained regulatory designations for zorevunersen including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, and maintains a strategic collaboration with Biogen under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights. The company is pursuing treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.
Cyborg Score Rationale
Analyst consensus rates STOK as "Strong Buy." 2024 revenue surged 316% to $36.56 million while losses decreased to $88.98 million. The company held $391.7 million in cash as of January 2026, expected to fund operations into 2028.
Top Insights
Phase 3 EMPEROR study enrollment expected to complete Q2 2026, with topline data planned for mid-2027 and rolling NDA initiation targeted in first half of 2027.
Phase 1 OSPREY study of STK-002 for ADOA launched with first patient dosed in early 2026.
Company signed lease for 98,500 square-foot headquarters in Waltham, MA, reflecting preparation for commercialization and platform expansion.
Zorevunersen is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome.
Named Competitors
Antisense Oligonucleotides (ASOs) — Co-developing zorevunersen for Dravet syndrome
Gene Therapy Platforms — Alternative approaches to genetic disease treatment
RNA Therapeutics — Competing RNA-based medicine platforms
Recent Developments
(February 2026) Phase 1 OSPREY study of STK-002 for ADOA launched with first patient dosed
(February 2026) Signed long-term lease for 98,500 sq ft headquarters in Waltham, MA
(January 2026) Updated zorevunersen Phase 3 timelines; completion expected Q2 2026 with mid-2027 data readout
Open the full interactive Stoke Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.